Medicare Enrolled
Dr. Ami Ben-Artzi, M.D.
Internal Medicine · Del Mar, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ben-Artzi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ben-Artzi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ben-Artzi
Dr. Ami Ben-Artzi is an internal medicine specialist in Del Mar, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Ben-Artzi performed 9,908 Medicare services across 1,191 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ben-Artzi received a total of $89,796 from 58 pharmaceutical and/or device companies across 835 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ben-Artzi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 2% volume in CA
$89,796 industry payments
Medicare Practice Summary
Medicare Utilization ↗9,908
Medicare services
Top 2% in CA for internal medicine
1,191
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~521 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 4,320 | $18 | $40 |
| Joint lubricant injection (Durolane) An injection of hyaluronan or its derivative, specifically Durolane, administered directly into a joint space. |
1,800 | $5 | $30 |
| Extended-release steroid injection (Zilretta) An injection of triamcinolone acetonide using a preservative-free, extended-release microsphere formulation. The dosage is measured in milligrams. |
864 | $13 | $30 |
| Hymovis intra-articular injection An injection of Hymovis, a hyaluronan derivative, administered directly into a joint space. |
672 | $13 | $25 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
608 | $91 | $264 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
358 | $138 | $325 |
| Complete ultrasound scan of joint An ultrasound exam that uses sound waves to create detailed images of a joint. This procedure allows for the visualization of the joint's internal structures. |
302 | $46 | $310 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
188 | $65 | $250 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
159 | $8 | $25 |
| Ultrasound-guided large joint aspiration or injection This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint. |
122 | $88 | $295 |
| Limited ultrasound of joint or extremity A focused ultrasound exam of a specific joint or other structure in the arm or leg, excluding blood vessels. |
79 | $36 | $167 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
74 | $1 | $10 |
| New patient office visit, complex (60-74 min) | 62 | $171 | $598 |
| Injection, methylprednisolone acetate, 40 mg | 59 | $6 | $16 |
| Venipuncture for blood draw Insertion of a needle into a vein to collect blood samples. This procedure is performed on patients aged 3 years or older. |
55 | $15 | $35 |
| Methylprednisolone acetate injection, 20 mg A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered. |
34 | $4 | $10 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
29 | $63 | $190 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
26 | $126 | $450 |
| Ultrasound-guided small joint aspiration or injection This procedure involves removing fluid from or injecting medication into a small joint while using ultrasound imaging to guide the needle placement. |
23 | $65 | $241 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
23 | $51 | $160 |
| Ultrasound-guided joint aspiration or injection Removal of fluid from or injection into a medium-sized joint using ultrasound guidance to ensure accurate placement. |
20 | $74 | $228 |
| Ultrasound guidance for needle placement Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure. |
18 | $45 | $269 |
| Tendon or ligament injection A procedure involving the injection of medication into a tendon or ligament. |
13 | $42 | $122 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$89,796
Total received (2018-2024)
Avg $12,828/year across 7 years
Top 2% in CA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
58
Companies
835
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$62,910 (70.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$17,558 (19.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$8,443 (9.4%)
Other
Charitable contributions, space rental, and other categories
$885 (1.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$10,163
2023
$2,645
2022
$2,518
2021
$2,726
2020
$5,789
2019
$39,716
2018
$26,239
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
UCB, Inc.
$7,143
Amgen Inc.
$507
ABBVIE INC.
$352
Janssen Biotech, Inc.
$318
Lilly USA, LLC
$281
ANI Pharmaceuticals, Inc.
$195
Mallinckrodt Hospital Products Inc.
$156
GlaxoSmithKline, LLC.
$144
Genentech USA, Inc.
$141
PFIZER INC.
$140
Radius Health, Inc.
$113
Fresenius Kabi USA, LLC
$105
GENZYME CORPORATION
$103
SANOFI-AVENTIS U.S. LLC
$98
Alexion Pharmaceuticals, Inc.
$75
Octapharma USA, Inc.
$69
SOBI, INC
$52
Biogen, Inc.
$44
Gilead Sciences, Inc.
$24
Grifols USA, LLC
$23
Novartis Pharmaceuticals Corporation
$22
Fidia Pharma USA Inc.
$21
Aurinia Pharma U.S., Inc.
$19
Currax Pharmaceuticals LLC
$16
Top 3 companies account for 78.7% of 2024 payments
All-time payments by company (2018-2024) ›
Mallinckrodt Enterprises LLC
$26,061
Mallinckrodt LLC
$23,335
UCB, Inc.
$8,128
Amgen Inc.
$7,826
Celgene Corporation
$6,975
Butterfly Network, Inc.
$1,999
Janssen Biotech, Inc.
$1,632
Horizon Therapeutics plc
$1,522
Gilead Sciences, Inc.
$1,515
GlaxoSmithKline, LLC.
$1,231
Lilly USA, LLC
$1,148
Esaote North America, Inc.
$885
PFIZER INC.
$767
Mallinckrodt Hospital Products Inc.
$763
ABBVIE INC.
$713
AbbVie, Inc.
$653
AbbVie Inc.
$546
Novartis Pharmaceuticals Corporation
$536
Radius Health, Inc.
$357
GENZYME CORPORATION
$312
ANI Pharmaceuticals, Inc.
$261
Janssen Scientific Affairs, LLC
$231
Genentech USA, Inc.
$221
SANOFI-AVENTIS U.S. LLC
$168
Aurinia Pharma U.S., Inc.
$164
DePuy Synthes Sales Inc.
$156
Fresenius Kabi USA, LLC
$133
Horizon Pharma plc
$111
Exeltis, USA Inc.
$109
Flexion Therapeutics, Inc.
$104
SOBI, INC
$95
AstraZeneca Pharmaceuticals LP
$94
MEDAC PHARMA, INC.
$88
Sobi, Inc
$83
Octapharma USA, Inc.
$83
Bioventus LLC
$76
Alexion Pharmaceuticals, Inc.
$75
Currax Pharmaceuticals LLC
$65
Fidia Pharma USA Inc.
$59
Pacira Pharmaceuticals Incorporated
$58
Antares Pharma, Inc.
$50
Averitas Pharma Inc.
$45
Biogen, Inc.
$44
CSL Behring
$29
Boehringer Ingelheim Pharmaceuticals, Inc.
$27
Cumberland Pharmaceuticals, Inc.
$26
E.R. Squibb & Sons, L.L.C.
$25
Grifols USA, LLC
$23
MEDEXUS PHARMA, INC.
$23
Takeda Pharmaceuticals U.S.A., Inc.
$23
Zimmer Biomet Holdings, Inc.
$22
Ultragenyx Pharmaceutical Inc.
$21
Novo Nordisk Inc
$19
Kyowa Kirin, Inc.
$19
Avanos Medical
$17
Azurity Pharmaceuticals, Inc.
$17
Teleflex LLC
$15
Sonex Health, Inc.
$14
Top 3 companies account for 64.1% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · BENLYSTA · Bimzelx · Butterfly iQ · CONTRAVE · COSENTYX · Cimzia · Durolane · EVENITY · Enbrel · Exparel · FORTEO · GATTEX · Gamunex-C · HUMIRA · HYMOVIS · Hizentra · Horizant · Humira · IDACIO · ILARIS · INFLECTRA · Iovera · JARDIANCE · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · MONOVISC · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ORENCIA · ORTHOVISC · OTREXUP · Otezla · Otrexup · PURIFIED CORTROPHIN GEL · Prolia · QUTENZA · RAYOS · REDITREX · REMICADE · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Sports Medicine Product Portfolio · Sx-One Microknife · TALTZ · TAVNEOS · TOFIDENCE · TREMFYA · TRIVISC SODIUM HYALURONATE · TZIELD · Tavneos · Titan SGS Standard Gastric Stapler · Tymlos · Wegovy · XELJANZ · XYOSTED · Xolair · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (70%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in internal medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for internal medicine in CA.
Geographic Context
Internal medicine physicians within 10 mi
1,624
Per 100K population
49.5
County median income
$102,285
Nearest hospital
VA SAN DIEGO HEALTHCARE SYSTEM
6.3 mi
6.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ben-Artzi is a mixed practice specialist, with above-average Medicare volume (top 2% in CA), with speaking/promotional industry engagement in the top 2% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ben-Artzi experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Ben-Artzi performed 4,320 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ben-Artzi receive payments from pharmaceutical companies?
Yes. Dr. Ben-Artzi received a total of $89,796 from 58 companies across 835 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ben-Artzi's costs compare to other internal medicine physicians in Del Mar?
Dr. Ben-Artzi's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ben-Artzi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Del Mar
Browse internal medicine physicians in Del Mar ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in CA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in CA
Which CA internal medicine physicians receive the most from drug and device companies.
By company
Mallinckrodt Enterprises LLC Payments to Doctors
See all physicians who received payments from Mallinckrodt Enterprises LLC.
By company
Mallinckrodt LLC Payments to Doctors
See all physicians who received payments from Mallinckrodt LLC.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology